2022
Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study
PELLI, Ari, Juhani M. JUNTTILA, Tuomas V. KENTTÄ, Simon SCHLÖGL, Markus ZABEL et. al.Základní údaje
Originální název
Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study
Autoři
PELLI, Ari, Juhani M. JUNTTILA (garant), Tuomas V. KENTTÄ, Simon SCHLÖGL, Markus ZABEL, Marek MALÍK (203 Česká republika, domácí), Tobias REICHLIN, Rik WILLEMS, Marc A. VOS, Markus HARDEN, Tim FRIEDE, Christian STICHERLING a Heikki V HUIKURI
Vydání
EP Europace, Oxford, Oxford University Press, 2022, 1099-5129
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 6.100
Kód RIV
RIV/00216224:14110/22:00125980
Organizační jednotka
Lékařská fakulta
UT WoS
000790073500001
Klíčová slova anglicky
Implantable cardioverter-defibrillator; Primary prevention; Mortality; Appropriate shock; Benefit; Heart failure; Electrocardiogram; Q wave; QT interval
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 10. 6. 2022 14:31, Mgr. Tereza Miškechová
Anotace
V originále
Aim The association of standard 12-lead electrocardiogram (ECG) markers with benefits of the primary prophylactic implantable cardioverter-defibrillator (ICD) has not been determined in the contemporary era. We analysed traditional and novel ECG variables in a large prospective, controlled primary prophylactic ICD population to assess the predictive value of ECG in terms of ICD benefit. Methods and results Electrocardiograms from 1477 ICD patients and 700 control patients (EU-CERT-ICD; non-randomized, controlled, prospective multicentre study; ClinicalTrials.gov Identifier: NCT02064192), who met ICD implantation criteria but did not receive the device, were analysed. The primary outcome was all-cause mortality. In ICD patients, the co-primary outcome of first appropriate shock was used. Mean follow-up time was 2.4 +/- 1.1 years to death and 2.3 +/- 1.2 years to the first appropriate shock. Pathological Q waves were associated with decreased mortality in ICD patients [hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.35-0.84; P < 0.01] and patients with pathological Q waves had significantly more benefit from ICD (HR 0.44, 95% CI 0.21-0.93; P = 0.03). QTc interval increase taken as a continuous variable was associated with both mortality and appropriate shock incidence, but commonly used cut-off values, were not statistically significantly associated with either of the outcomes. Conclusion Pathological Q waves were a strong ECG predictor of ICD benefit in primary prophylactic ICD patients. Excess mortality among Q wave patients seems to be due to arrhythmic death which can be prevented by ICD.